Aegis remains bullish on BioLineRx after upbeat BL-8040 news

• Aegis' Raghuram Selvaraju is sticking with a Buy rating and a $7 target on shares of BioLineRx (BLRX +13.3%) after today's BL-8040 update.
• "It appears to [provide] a dual-layered benefit to patients," Selvaraju says, referencing the company's suggestion that the drug may make cancer cells more susceptible to chemo and may also contribute to cell death.